OSI Pharmaceuticals, Inc. Announces Occurrence of a Fundamental Change for Convertible Notes

Published: Jun 10, 2010

MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (the “Company”) announced today that its 2% Convertible Senior Subordinated Notes due 2025 (the “notes”) are convertible at the option of the holders and will remain convertible at least through July 8, 2010, as provided for in the Indenture (the “Indenture”) governing the notes.

Back to news